Interleukin-26 Linked to Severe COVID-19 and Lung Conditions

Medical News: A groundbreaking study has uncovered a link between a protein in the body known as Interleukin-26 (IL-26) and severe COVID-19 cases, especially in patients with obstructive lung diseases such as asthma and COPD. Researchers from the Karolinska Institutet in Sweden, the University of Gothenburg, and Meso Scale Diagnostics, LLC., USA, led the study, shedding light on how this protein could play a significant role in the severity of COVID-19.


Interleukin-26 Linked to Severe COVID-19 and Lung Conditions

The study analyzed blood samples from patients with varying COVID-19 severity and compared them to healthy controls. This Medical News report dives into the key findings of the study, emphasizing how IL-26 can potentially be used as a biomarker for disease severity and its connection to other important health factors.

What is IL-26?
IL-26 is a protein primarily found in the airways and has long been recognized for its role in defending the body against bacterial infections. However, recent studies have expanded its importance, suggesting that IL-26 may also help the body fight off viruses. In COVID-19 patients, previous research had already indicated that IL-26 levels increased, contributing to harmful inflammation in the lungs. What wasn’t clear, though, was whether IL-26 was directly connected to how severe the disease became.
 
The researchers behind this study set out to answer that question by studying IL-26 levels in different COVID-19 patients and correlating the data with disease severity, viral load, and specific immune responses.
 
Study Overview
A total of 178 patients with confirmed COVID-19 were included in the study, along with a control group of 30 healthy individuals. The patients were classified into three groups: mild, moderate, and severe/critical, depending on their symptoms and the level of medical intervention required. The researchers measured the IL-26 levels in their blood samples, alongside other markers like viral proteins and interferons, to investigate the role of IL-26 in COVID-19 progression.
 
IL-26 concentrations were assessed using specialized blood tests, such as enzyme-linked immunosorbent assay (ELISA). The study covered various parameters to ensure accurate comparisons, such as the time since symptom onset, length of hospital stay, and other health conditions the patients had before contracting COVID-19.
 
IL-26 and Severe COVID-19
One of the most important findings from the study is that IL-26 levels were significantly higher in patients with severe or critical COVID-19 compared to those with mild or moderate forms of the disease. In fact, the number of patients with detectable levels of IL-26 increased with the severity of the disease. Only 10% of mild cases showed elevated IL-26 levels, compared to 55% of severe cases.
 
Moreover, the study found a direct link between IL-26 levels and how long a patient had to stay in the hospital. Patients with high IL-26 levels generally had longer hospital stays, suggesting that this protein could be a strong indicator of disease severity. Interestingly, men were more likely to have higher IL-26 levels than women, which aligns with the observation that men tend to have more severe COVID-19 outcomes.
 
Comorbidities and IL-26
The study also revealed a notable connection between IL-26 and pre-existing respiratory conditions like asthma and COPD. Patients with these conditions showed much higher levels of IL-26 in their blood than those without such diseases. This suggests that people with obstructive lung diseases are not only more vulnerable to severe COVID-19 but that their heightened IL-26 levels might explain why they fare worse than others when infected.
 
This finding is particularly important as it helps explain the higher risks for COVID-19 patients with underlying lung conditions. These patients have consistently faced longer recoveries and worse outcomes during the pandemic, and IL-26 could be a key factor in understanding why.
 
IL-26 and Viral Load
Another aspect of the study focused on the relationship between IL-26 and viral load, which refers to the amount of virus present in the patient’s system. Researchers measured the levels of specific COVID-19 proteins in the patients’ blood and found that those with higher IL-26 levels also had more viral proteins. This suggests that IL-26 might be part of the body’s response to higher viral loads, possibly trying to fight off the virus but also contributing to excessive inflammation in the process.
 
The findings from this part of the study reinforce the role of IL-26 in fighting infections but also highlight the potential downside. While IL-26 helps mobilize immune cells and promotes the body’s defenses, it might also worsen inflammation, leading to more severe disease symptoms, particularly in COVID-19.
 
IL-26 and the Immune Response
The immune system’s response to viruses is often measured through the production of proteins called interferons. These proteins play a vital role in the body’s ability to detect and fight off viral infections. In this study, researchers found that IL-26 levels correlated with interferon levels, particularly interferon-gamma (IFN-g). Both IL-26 and IFN-g were present in higher concentrations in patients with severe disease, suggesting that these proteins might work together to fight COVID-19.
 
What is particularly interesting about this connection is that both IL-26 and interferons have been shown to inhibit viral replication. However, in the context of severe COVID-19, this immune response can sometimes backfire, leading to an overly aggressive inflammatory response, known as a “cytokine storm,” which can damage tissues and worsen the disease.
 
The Role of IL-26 in Inflammation
One of the key findings in the study is the relationship between IL-26 and markers of tissue damage. The researchers measured levels of double-stranded DNA (dsDNA) in the blood, which is an indicator of cell death and tissue damage. High levels of dsDNA were associated with more severe COVID-19, and IL-26 levels were positively correlated with dsDNA. This indicates that IL-26 may be linked to the tissue damage seen in severe COVID-19 cases.
 
The connection between IL-26 and tissue damage could help explain why some patients develop life-threatening symptoms. As the body ramps up its defense mechanisms, including the production of IL-26, it may inadvertently cause more harm than good by damaging healthy tissue, particularly in the lungs.
 
Conclusions
In summary, this study shows that IL-26 is a critical player in the body’s response to COVID-19, particularly in severe cases. Patients with high IL-26 levels were more likely to experience severe disease, longer hospital stays, and more tissue damage. These findings are especially relevant for patients with pre-existing respiratory conditions like asthma and COPD, who tend to have higher IL-26 levels to begin with.
 
The research suggests that IL-26 could be a useful biomarker for identifying patients at risk of severe COVID-19, especially those with lung conditions. Targeting IL-26 or managing its effects on the body could offer new treatment strategies to help reduce the severity of COVID-19 and improve patient outcomes.
 
The study findings were published in the peer-reviewed journal: Frontiers in Immunology.
https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1434186/full
 
For the latest COVID-19 News, keep on logging to Thailand Medical News.
 
Read Also:
https://www.thailandmedical.news/news/il-27-dual-role-as-either-a-preventor-or-promoter-of-covid-19
 
https://www.thailandmedical.news/news/altered-serum-concentrations-of-il-8-il-10-and-il-32-in-individuals-with-lung-impairment-6-months-after-covid-19